Serum YKL-40 concentrations in patients with rheumatoid arthritis: Relation to disease activity

Rheumatology

Volumn 38, Issue 7, 1999, Pages 618-626

  Johansen, J S ^a,b   Stoltenberg, M ^a   Hansen, M ^a   Florescu, A ^b   Horslev Petersen K ^a   Lorenzen, I ^a   Price, P A ^c  

^a HVIDOVRE HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Disease activity; Human cartilage glycoprotein 39; Rheumatoid arthritis; YKL 40

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; GLYCOPROTEIN GP 39; GOLD; HYDROXYCHLOROQUINE; METHOTREXATE; PENICILLAMINE; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; DISEASE ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FEMALE; GLYCOPROTEINS; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PREDNISOLONE; SEVERITY OF ILLNESS INDEX;

EID: 0032706496     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/38.7.618     Document Type: Article

References (40)

1. Harris ED Jr. Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med 1990;322:1277-89.
2. Klareskog L, Forsum U, Scheynius A, Kabelitz D, Wigzell H. Evidence in support of a self-perpetuating HLA-DR-dependent delayed-type cell reaction in rheumatoid arthritis. Proc Natl Acad Sei USA 1982;70:3632-6.
3. Panayi GS, Lanchbury JS, Kingsley GH. The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum 1992;35:729-35.
4. Fox DA. The role of T cells in immunopathogenesis of rheumatoid arthritis. Arthritis Rheum 1997;40:598-609.
5. Hakala BE, White C, Recklies AD. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem 1993;268:25803-10.
6. Johansen JS, Jensen HS, Price PA. A new biochemical marker for joint injury. Analysis of YKL-40 in serum and synovial fluid. Br J Rheumatol 1993;32:949-55.
7. Hu B, Trinh K, Figueira WF, Price PA. Isolation and sequence of a novel human chondrocyte protein related to mammalian members of the chitinase protein family. J Biol Chem 1996;271:19415-20.
8. Krause SW, Rehli M, Kreutz M, Schwarzfischer L, Paulauskis JD, Andreesen R. Differential screening identifies genetic markers of monocyte to macrophage maturation. J Leuk Biol 1996;60:540 5.
9. Shackelton LM, Mann DM, Millis AJT. Identification of a 38-kDa heparin-binding glycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodelling. J Biol Chem 1995;270:13076-83.
10. Morrison BW, Leder P. neu and ras initiate murine mammary tumors that share genetic markers generally absent in c-myc and int-2-initiated tumors. Oncogene 1994;9:3417-26.
11. Verheijden GFM, Rijnders AWM, Bos E, Coenen-de Roo CJJ, Van Staveren CJ, Miltenburg AMM et al. Human cartilage glycoprotein-39 as a candidate autoantigen in rheumatoid arthritis. Arthritis Rheum 1997;40:1115-25.
12. Renkema GH, Boot RG, Au FL, Donker-Koopman WE, Strijland A, Muijsers AO et al. Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. Eur J Biochem 1998;251:504-9.
13. Nyirkos P, Golds EE. Human synovial cells secrete a 39 kDa protein similar to a bovine mammary protein expressed during the non-lactating period. Biochem J 1990;268:265-8.
14. Kirkpatrick RB, Emery JG, Connor JR, Dodds R, Lysko PG, Rosenberg M. Induction and expression of human cartilage glycoprotein 39 in rheumatoid inflammatory and peripheral blood monocyte-derived macrophages. Exp Cell Res 1997;237:46-54.
15. Volck B, Price PA, Johansen JS, Sørensen O, Benfield T, Nielsen HJ et al. YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Physicians 1998; 110:351-60.
16. Johansen JS, Williamson MK, Rice JS, Price PA. Identification of proteins secreted by human osteoblastic cells in culture. J Bone Miner Res 1992;7:501-12.
17. Rehli M, Krause SW, Andreesen R. Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics 1997;43:221-5.
18. Rejman JJ, Hurley WL. Isolation and characterization of a novel 39 kilodalton whey protein from bovine mammary secretions collected during the nonlactating period. Biochem Biophys Res Commun 1988;150:329-34.
19. Johansen JS, Møller S, Price PA, Bendtsen F, Junge J, Garbarsch C et al. Plasma YKL-40: a new potential marker of fibrosis in patients with alcoholic cirrhosis? Scand J Gastroenterol 1997;32:582-90.
20. Johansen JS, Hvolris J, Hansen M, Backer V, Lorenzen I, Price PA. Serum YKL-40 levels in healthy children and adults. Comparison with serum and synovial fluid levels of YKL-40 in patients with osteoarthritis or trauma of the knee joint. Br J Rheumatol 1996;35:553-9.
21. Hansen M, Florescu A, Stoltenberg M, Pødenphant J, Pedersen-Zbinden B, Hørslev-Petersen K et al. Bone loss in rheumatoid arthritis. Influence of disease activity, duration of the disease, functional capacity, and corticosteroid treatment. Scand J Rheumatol 1996;25:367-76.
22. Hansen M, Pødenphant J, Florescu A, Stoltenberg M, Borch A, Kluger E et al. A randomised trial of differentiated prednisolone therapy in active rheumatoid arthritis. Clinical benefits and skeletal side effects. Ann Rheum Dis 1999; in press.
23. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
24. Steinbrocker O, Traeger Ch, Batterman RC. Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc 1949;140:659-62.
25. Lansbury J, Haut DD. Quantitation of the manifestations of rheumatoid arthritis. 4. Area of joint surfaces as an index to total joint inflammation and deformity. Am J Med Sci 1956;232:150-5.
26. Risteli J, Niemi S, Trivedi P, Mäentausta O, Mowat P, Risteli L. Rapid equilibrium radioimmunoassay for the amino-terminal propeptide of human type III procollagen. Clin Chem 1988;34:715-8.
27. Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn 1977;18:481-91.
28. Matthews JNS, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. Br Med J 1990;300:230-5.
29. van Leeuwen MA, van der Heijde DMFM, van Rijswijk MH, Houtman PM, van Riel PLCM, van de Putte LBA et al. Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts and acute phase reactants. J Rheumatol 1994;21:425-9.
30. Emery P, Luqmani R. The validity of surrogate markers in rheumatic disease. Br J Rheumatol 1993;32(suppl. 3):3-8.
31. Otterness IG. The value of C-reactive protein measurement in rheumatoid arthritis. Semin Arthritis Rheum 1994; 24:91-104.
32. Scott DL, Coulton BL, Popert AJ. Long term progression of joint damage in rheumatoid arthritis. Ann Rheum Dis 1986;45:373-8.
33. Kirwan JR, Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 1995;333:142-6.
34. Hørslev-Petersen K, Bentsen KD, Engström-Laurent A, Junker P, Halberg P, Lorenzen I. Serum amino terminal type III procollagen peptide and serum hyaluronan in rheumatoid arthritis: relation to clinical and serological parameters of inflammation during 8 and 24 months' treatment with levamisole, penicillamine or azathioprine. Ann Rheum Dis 1988;47:116-26.
35. Hørslev-Petersen K, Bentsen KD, Junker P, Lorenzen I. Serum aminoterminal type III procollagen peptide in rheumatoid arthritis. Relationship to disease activity, treatment and development of joint erosions. Arthritis Rheum 1986;29:592-9.
36. Baumann H, Gauldie J. The acute phase response. Immunol Today 1994;15:74-80.
37. Gauldie J, Richards C, Baumann H. IL6 and the acute phase reaction. Res Immunol 1992;143:755-9.
38. Philliger MH, Abramson SB. The neutrophil in rheumatoid arthritis. Rheum Dis Clin North Am 1995;21:691-714.
39. Mohr W, Westerhellweg H, Wessinghage D. Polymorphonuclear granulocytes in rheumatic tissue destruction III. An electron microscopic study of PMNs at the pannus-cartilage junction in rheumatoid arthritis. Ann Rheum Dis 1981;40:396-9.
40. Chatham WW, Swaim R, Frohsin H Jr, Heck LW, Miller EJ, Blackburn WD Jr. Degradation of human articular cartilage by neutrophils in synovial fluid. Arthritis Rheum 1993;36:51-8.